ERA - India

ERA
Benefits
Indications

What is the ERA test?

The Endometrial Receptivity Analysis (ERA), developed and patented by Igenomix (PCT/ ES2009/000386), is a test designed to evaluate endometrial receptivity.

This molecular diagnostic tool uses NGS to analyse the expression level of 248 genes related to the status of endometrial receptivity.

The ERA test has been shown to be highly sensitive and specific in the detection of genetic expression profiles associated with receptivity. It allows the personalised window of implantation to be detected before the patient starts using assisted reproduction techniques.

To do so, RNA obtained from an endometrial tissue sample is analysed and the endometrial receptivity profile is classified by our ERA predictor.

The high-resolution of ERA enables us to designate the endometrium across the spectrum of pre-receptive – early-receptive – receptive – late-receptive – post-receptive. This detailed identification of a patient’s personalised window of implantation allows us to recommend a precise (+/- 3 hours) timing for embryo transfer.

What is the procedure?

Why use ERA test?

ERA is backed by 33 publications; 29 from Igenomix and 4 external publications.
Randomized clinical trial (NCT01954758) RCT proves Cum. Pregnancy rate increases +22 points VS classic fresh blastocyst transfer in first appointment patients:
72.5%* pregnancy rate using ERA in the first IVF cycle in any patient.
ERA is backed by 21 publications; 13 from Igenomix and 8 external publications.
Proprietary algorithm based on machine learning that minimises the need for a second biopsy to only 10% of cases

Who should use ERA test?

Women who have experienced implantation failure with morphologically good quality embryos
Women who have an atrophic endometrium (< 6mm) present higher risk of having a displaced WOI.

When to perform ERA to your Patient?

How should I collect and send the sample?

An endometrial biopsy taken from the uterine fundus must be immediately place into an ERA cryotube, shaken and stored in a refrigerator (4-8°C/ 39-46°F) for at least 4 hours.

Samples are sent at room temperature(<35ºC/95ºF) accompanied with the patient´s informed consent and a completed requisition form.

When is the second endometrial biopsy needed?

90 % of cases don’t need a second biopsy. The second biopsy is only required under two circumstances:

Patients with a “Pre-receptive” result needing 2 more days with progesterone.
Patients with a “Post-receptive” result

Test limitations

There is a risk (<5%) of a non-informative result when the biopsy procedure has failed to obtain a sufficient quantity and/or quality of tissue to be able to make a diagnosis. If this should occur a new biopsy will be required.
The aim of this test Is to provide physicians with an objective molecular diagnosis of the patient’s endometrial receptivity window. Depending on the results of this test, the physician may use it as a guide for a personalised embryo transfer.
Pregnancy is not guaranteed, even with a receptive result. Poor embryo quality, genetic abnormalities, or previous pathologies can also reduce the likelihood of becoming pregnant.
ERA® does not test for any other endometrial pathology and does not asses or provide a prediction for the health of a subsequent pregnancy.

*Simón et al., In vitro fertilization with personalized blastocyst transfer versus frozen or fresh blastocyst transfer: a multicenter, randomized clinical trial. Fertility and Sterility, 2019; 112. e56-e57. 10.1016/j.fertnstert.2019.07.273.

**Oral presentation, Clemente-Císcar, ESRHE 2018

Scientific evidence

A genomic diagnostic tool for human endometrial receptivity based on the transcriptomic signature.

Díaz-Gimeno P, Horcajadas JA, Martínez-Conejero JA, Esteban FJ, Alamá P, Pellicer A, Simón C.
Fertil Steril. 2011 Jan;95(1):50-60, 60.e1-15. doi: 10.1016/j.fertnstert.2010.04.063. Epub 2010 Jul 8.

PMID:20619403

The accuracy and reproducibility of the endometrial receptivity array is superior to histology as a diagnostic method for endometrial receptivity.

Díaz-Gimeno P, Ruiz-Alonso M, Blesa D, Bosch N, Martínez-Conejero JA, Alamá P, Garrido N, Pellicer A, Simón C.
Fertil Steril. 2013 Feb;99(2):508-17. doi: 10.1016/j.fertnstert.2012.09.046. Epub 2012 Oct 23.

PMID:23102856

The endometrial receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure.

Ruiz-Alonso M, Blesa D, Díaz-Gimeno P, Gómez E, Fernández-Sánchez M, Carranza F, Carrera J, Vilella F, Pellicer A, Simón C.
Fertil Steril. 2013 Sep;100(3):818-24. doi: 10.1016/j.fertnstert.2013.05.004. Epub 2013 Jun 4.

PMID:23756099

The impact of using the combined oral contraceptive pill for cycle scheduling on gene expression related to endometrial receptivity.

Bermejo A, Iglesias C, Ruiz-Alonso M, Blesa D, Simón C, Pellicer A, García-Velasco J.
Hum Reprod. 2014 Jun;29(6):1271-8. doi: 10.1093/humrep/deu065. Epub 2014 Apr 4.

PMID:24706003

What a difference two days make: “personalized” embryo transfer (pET) paradigm: a case report and pilot study.

Ruiz-Alonso M, Galindo N, Pellicer A, Simón C.
Hum Reprod. 2014 Jun;29(6):1244-7. doi: 10.1093/humrep/deu070. Epub 2014 Apr 15.

PMID:24737781

Timing the window of implantation by nucleolar channel system prevalence matches the accuracy of the endometrial receptivity array.

Nejat EJ, Ruiz-Alonso M, Simón C, Meier UT. Fertil Steril. 2014 Nov;102(5):1477-81. doi: 10.1016/j.fertnstert.2014.07.1254. Epub 2014 Sep 17.

PMID25241377

Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression.

Bermejo A, Cerrillo M, Ruiz-Alonso M, Blesa D, Simón C, Pellicer A, Garcia-Velasco JA. Fertil Steril. 2014 Jan;101(1):138-146.e3. doi: 10.1016/j.fertnstert.2013.09.033. Epub 2013 Oct 29.

PMID:24182413

Is endometrial receptivity transcriptomics affected in women with endometriosis? A pilot study.

Garcia-Velasco JA, Fassbender A, Ruiz-Alonso M, Blesa D, D’Hooghe T, Simon C. Reprod Biomed Online. 2015 Nov;31(5):647-54. doi: 10.1016/j.rbmo.2015.07.014. Epub 2015 Aug 11.

PMID:26385059

Intrauterine human chorionic gonadotropin infusion in oocyte donors promotes endometrial synchrony and induction of early decidual markers for stromal survival: a randomized clinical trial.

Strug MR, Su R, Young JE, Dodds WG, Shavell VI, Díaz-Gimeno P, Ruíz-Alonso M, Simón C, Lessey BA, Leach RE, Fazleabas AT. Hum Reprod. 2016 Jul;31(7):1552-61. doi: 10.1093/humrep/dew080. Epub 2016 Apr 26.

PMID:27122490

Window of implantation transcriptomic stratification reveals different endometrial subsignatures associated with live birth and biochemical pregnancy.

Díaz-Gimeno P, Ruiz-Alonso M, Sebastian-Leon P, Pellicer A, Valbuena D, Simón C. Fertil Steril. 2017 Oct;108(4):703-710.e3. doi: 10.1016/j.fertnstert.2017.07.007. Epub 2017 Aug 30.

PMID:28863933

Inter-cycle consistency versus test compliance in endometrial receptivity analysis test.

Stankewicz T, Valbuena D, Ruiz-Alonso M.

J Assist Reprod Genet. 2018 May 26. doi: 10.1007/s10815-018-1212-7

Effect of mifepristone on the transcriptomic signature of endometrial receptivity.

von Grothusen C, Lalitkumar PG, Ruiz-Alonso M, Boggavarapu NR, Navarro R, Miravet-Valenciano J, Gemzell-Danielsson K, Simon C.

Hum Reprod. 2018 Aug 22. doi: 10.1093/humrep/dey272. [Epub ahead of print] PMID: 30137464

Live birth after embryo transfer in an unresponsive thin endometrium.

Cruz, J. Bellver.

Gynecol Endocrinol. 2014 Jul;30(7):481-4. doi: 10.3109/09513590.2014.900747. Epub 2014 Mar 20.

Endometrial receptivity array: Clinical application.

Mahajan N.

J Hum Reprod Sci. 2015 Jul-Sep;8(3):121-9. doi: 10.4103/0974-1208.165153. Review.

PMID:26538853

Efficacy of the endometrial receptivity array for repeated implantation failure in Japan: A retrospective, two-centers study.

Hashimoto T, Koizumi M, Doshida M, Toya M, Sagara E, Oka N, Nakajo Y, Aono N, Igarashi H, Kyono K.

Reprod Med Biol. 2017 Jun 27;16(3):290-296. doi: 10.1002/rmb2.12041. eCollection 2017 Jul.

PMID:29259480

The role of the endometrial receptivity array (ERA) in patients who have failed euploid embryo transfers.

Tan J, Kan A, Hitkari J, Taylor B, Tallon N, Warraich G, Yuzpe A, Nakhuda G.

J Assist Reprod Genet. 2018 Jan 11. doi: 10.1007/s10815-017-1112-2.

PMID:29327111

The Reproductive Outcomes for the Infertile Patients with Recurrent Implantation Failures May Be Improved by Endometrial Receptivity Array Test.

Ota, T., Funabiki, M., Tada, Y., Karita, M., Hayashi, T., Maeda, K. et al.

Journal of Medical Cases. 2019; 10(5), 138-140. doi: https://doi.org/10.14740/jmc3282

Why results of endometrial receptivity assay testing should not be discounted in recurrent implantation failure?
Simrandeep K., Padmaja N. The Onco Fertility Journal. 2019; 2(1): 46-49.

Personalized Embryo Transfer Helps in Improving In vitro Fertilization/ICSI Outcomes in Patients with Recurrent Implantation Failure.

Patel JA, Patel AJ, Banker JM, Shah SI, Banker MR. J Hum Reprod Sci. 2019; 12(1):59-66. doi: 10.4103/jhrs.JHRS_74_18.

Endometrial Receptivity Analysis – a tool to increase an implantation rate in assisted reproduction.

Hromadová L; Tokareva I; Veselá K; Trávník P; Veselý J. Ceska Gynekol. 2019; 84(3): 177-183.

Igenomix and fertility

We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive.

Learn more about Igenomix

Other services you may be interested

EndomeTRIO

A new dimension of endometrial health

More information

EMMA

Evaluates the endometrium at the microbiological level

More information

ALICE

Detects the bacteria causing chronic endometritis

More information

Sex selection and Sex determination, before and after conception is prohibited and punishable under PC & PNDT act no. 57 of 1994

Igenomix is in the media

Talk with friends or family sharing this info

72.5%*pregnancy rate using ERA in the first IVF cycle in any patient

Supported by 13 internal and 8 external publications

3 out of 10 patients have their implantation window shifted**

Are you interested?

What is the ERA test?

What is the procedure?

Why use ERA test?

Who should use ERA test?

When to perform ERA to your Patient?

How should I collect and send the sample?

When is the second endometrial biopsy needed?

Test limitations

Relevant related studies:

Can we help you?

Igenomix and fertility

EndomeTRIO

EMMA

ALICE

Igenomix is in the media

ERA® Endometrial Receptivity Analysis

The ERA test evaluates the receptivity of the endometrium to determine if, at the time of biopsy, the uterine lining is receptive to embryo implantation. This information allows us to determine the ideal time for a personalised embryo transfer (pET).

72.5%*pregnancy rate using ERA in the first IVF cycle in any patient

Supported by 13 internal and 8 external publications

3 out of 10 patients have their implantation window shifted**

Are you interested?

What is the ERA test?

What is the procedure?

Why use ERA test?

Who should use ERA test?

When to perform ERA to your Patient?

How should I collect and send the sample?

When is the second endometrial biopsy needed?

Test limitations

Relevant related studies:

Can we help you?

Igenomix and fertility

Other services you may be interested

EndomeTRIO

EMMA

ALICE

Sex selection and Sex determination, before and after conception is prohibited and punishable under PC & PNDT act no. 57 of 1994

Igenomix is in the media